A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 11,300 shares of KROS stock, worth $193,456. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,300
Previous 1,200 841.67%
Holding current value
$193,456
Previous $54,000 1114.81%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$41.68 - $58.07 $12.3 Million - $17.1 Million
294,439 Added 71.73%
704,923 $40.9 Million
Q2 2024

Aug 14, 2024

SELL
$44.58 - $66.89 $1.77 Million - $2.66 Million
-39,794 Reduced 8.84%
410,484 $18.8 Million
Q1 2024

May 15, 2024

SELL
$41.26 - $70.48 $12.8 Million - $21.8 Million
-309,890 Reduced 40.77%
450,278 $29.8 Million
Q4 2023

Feb 14, 2024

BUY
$27.12 - $41.05 $9.63 Million - $14.6 Million
355,019 Added 87.63%
760,168 $30.2 Million
Q3 2023

Nov 14, 2023

BUY
$31.57 - $43.02 $2.44 Million - $3.33 Million
77,349 Added 23.6%
405,149 $12.9 Million
Q2 2023

Aug 14, 2023

SELL
$37.26 - $51.01 $1.63 Million - $2.23 Million
-43,683 Reduced 11.76%
327,800 $13.2 Million
Q1 2023

May 15, 2023

SELL
$41.44 - $59.32 $1.41 Million - $2.02 Million
-33,988 Reduced 8.38%
371,483 $15.9 Million
Q4 2022

Feb 14, 2023

SELL
$39.45 - $51.77 $892,990 - $1.17 Million
-22,636 Reduced 5.29%
405,471 $19.5 Million
Q3 2022

Nov 14, 2022

BUY
$27.8 - $40.12 $2.05 Million - $2.96 Million
73,753 Added 20.81%
428,107 $16.1 Million
Q2 2022

Aug 15, 2022

BUY
$26.03 - $67.04 $1.93 Million - $4.97 Million
74,193 Added 26.48%
354,354 $9.79 Million
Q1 2022

May 16, 2022

BUY
$42.12 - $59.36 $128,845 - $181,582
3,059 Added 1.1%
280,161 $15.2 Million
Q4 2021

Feb 14, 2022

BUY
$36.95 - $62.89 $102,610 - $174,645
2,777 Added 1.01%
277,102 $16.2 Million
Q3 2021

Nov 15, 2021

BUY
$29.27 - $43.71 $4.58 Million - $6.84 Million
156,377 Added 132.58%
274,325 $10.9 Million
Q2 2021

Aug 16, 2021

SELL
$42.4 - $70.11 $423,024 - $699,487
-9,977 Reduced 7.8%
117,948 $5.01 Million
Q1 2021

May 17, 2021

SELL
$54.0 - $75.28 $7.63 Million - $10.6 Million
-141,318 Reduced 52.49%
127,925 $7.87 Million
Q4 2020

Feb 16, 2021

BUY
$36.0 - $82.74 $9.69 Million - $22.3 Million
269,243 New
269,243 $19 Million
Q3 2020

Nov 16, 2020

SELL
$27.04 - $62.21 $4.25 Million - $9.79 Million
-157,333 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$20.08 - $40.39 $3.16 Million - $6.35 Million
157,333 New
157,333 $5.9 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $441M
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.